At a Glance
- Company: Sanofi
- Location: Paris, France (global operations)
- Deal value: Drug acquired in a $3.7 billion Principia Biopharma buyout
- Focus area: BTK inhibitor tolebrutinib for progressive forms of multiple sclerosis
- Next steps: No longer pursuing primary progressive MS; awaiting updated FDA guidance for non‑relapsing SPMS by end of Q1 2026
What happened?
Sanofi reported that its experimental MS therapy tolebrutinib failed to meet the primary endpoint in the PERSEUS Phase 3 trial in primary progressive multiple sclerosis (PPMS), which assessed delay in disability progression in 767 patients. At the same time, the company said the US Food and Drug Administration will again delay its decision on tolebrutinib for non‑relapsing secondary progressive MS (nrSPMS), pushing review beyond the previous 28 December 2025 action date.
Why does it matter?
Tolebrutinib is one of Sanofi’s most advanced late‑stage neurology assets and a key part of its MS strategy, so the PPMS failure removes a potentially important indication. The additional FDA delay for nrSPMS extends uncertainty over if and how the drug will reach the US market, weighing on Sanofi’s growth plans and contributing to a share price drop of around 6% in Paris trading.
Who’s behind it?
Sanofi developed tolebrutinib after acquiring the BTK inhibitor through its $3.7 billion takeover of Principia Biopharma in 2021. The company has been running a broad late‑stage MS programme, including trials in relapsing and progressive forms of the disease, and holds breakthrough therapy designation for certain indications.
How was it achieved?
PERSEUS is a Phase 3, placebo‑controlled study in PPMS designed to test whether tolebrutinib could delay disability progression, but the drug did not meet its primary endpoint. Safety findings, including risks of drug‑induced liver injury previously seen in the programme and which prompted a partial FDA clinical hold, were described as consistent with earlier trials, reinforcing the need for liver monitoring. In parallel, the FDA’s ongoing review of nrSPMS has been extended, with Sanofi expecting further regulatory guidance by the end of the first quarter of 2026.
What’s next?
Sanofi has stated it will not pursue regulatory registration of tolebrutinib for PPMS and will reassess the asset’s value, including a potential impairment charge. The company plans to present full PERSEUS data at an upcoming medical meeting, while discussions with the FDA continue on the nrSPMS application and on how the totality of efficacy and safety data will shape any potential label.
What are people saying?
Analysts note that the dual setback further complicates the already challenging progressive MS space and may limit tolebrutinib’s peak sales potential even if nrSPMS approval is eventually secured. Sanofi has emphasised its unchanged 2025 financial guidance and framed the outcome as a data‑driven decision focused on indications where the benefit–risk profile appears strongest.